<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
CONNECTIVE THERAPEUTICS, INC.
- -------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.001 Par Value
- -------------------------------------------------------------------------------
(Title of Class of Securities)
207854100
- -------------------------------------------------------------------------------
(CUSIP Number)
Donald F. Parman, SmithKline Beecham Properties, Ltd.
One Franklin Plaza, Philadelphia, PA 19102
Telephone 215-751-7633
- -------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
December 31, 1996
- -------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
<PAGE> 2
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.
Check the following box if a fee is being paid with the statement / /. (A fee
is not required only if the reporting person: (1) has a previous statement on
file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are to
be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE> 3
SCHEDULE 13D
CUSIP NO. 207854100 PAGE 2 OF 5 PAGES
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
SmithKline Beecham Properties, Ltd.
51-0304934
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
OO
- -------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(D) OR 2(E) [ ]
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- -------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF
SHARES 637,733
BENEFICIALLY ----------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING None
PERSON -----------------------------------------------------------------
WITH 9 SOLE DISPOSITIVE POWER
637,733
-----------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
None
- -------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
637,733
- -------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* [ ]
- -------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.89%
- -------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- -------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE> 4
Page 3 of 5 Pages
Item 1. Security and Issuer.
Common Stock, $.001 par value per share
Connective Therapeutics, Inc.
3400 West Bayshore Road
Palo Alto, California 94303
Item 2. Identity and Background.
(a) The name of the person filing this Schedule is:
SmithKline Beecham Properties, Ltd. ("SBP"), a
Delaware corporation, the record holder of the shares which are the subject of
this report, is a wholly owned subsidiary of SmithKline Beecham plc engaged in
finance and investment activities principally within the SmithKline Beecham
group.
(b) The principal business address of SBP is:
1403 Foulk Road
Suite 102
P.O. Box 7108
Wilmington, DE 19803-2775
(c) Information concerning SBP is set forth in response
to Item 2(a) above.
(d) During the last five years, SBP has not been
convicted in a criminal proceeding, excluding traffic violations or similar
misdemeanors.
(e) During the last five years SBP was not a party to a
civil proceeding of a judicial or administrative body of competent jurisdiction
and as a result thereof subject to a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities subject to Federal
or State securities laws or finding any violation with respect to such laws.
(f) Not applicable.
Item 3. Source and Amount of Funds or Other Consideration.
SBP acquired 637,733 shares of the Common Stock, $.001 par value per
share, of the Issuer on December 31, 1996, in a private placement as partial
consideration for sale to Issuer of the RIDAURA brand of auranofin in the
United States, Canada and Puerto Rico.
Item 4. Purpose of Transaction.
SBP intends to review from time to time the business affairs and
financial position of the Issuer. Based on such evaluation and review, as well
as general economic and industry conditions existing at the time and SBP's own
financial plans, SBP may consider from time to time various alternative courses
of action. Such action may include the acquisition of additional shares
through open market purposes, privately negotiated transactions or otherwise.
Alternatively, such actions may involve the sale of all or a portion of the
shares in the open market, in privately negotiated transactions, through public
offering or otherwise. All of the securities acquired have been acquired for
investment purposes.
<PAGE> 5
Page 4 of 5 Pages
Item 5. Interest in Securities of the Issuer.
(a) Amount and Percent Beneficially Owned
Registered Name No. of Shares Percent
--------------- ------------- -------
SmithKline Beecham Properties, Ltd. 637,733 7.89%
(b) SBP has sole voting and investment power with respect to the
637,733 shares of Common Stock identified in subparagraph (a) above.
(c) The only transactions involving SBP and the Common Stock of
the Issuer are the transactions referenced above.
(d) Except for SBP's right, as a shareholder of the Issuer, to
receive a portion of dividends from, or the proceeds from the sale of, the
securities referenced above, no person is known to have the right to receive or
the power to direct the receipt of dividends from, or the proceeds from the
sale of, the securities referenced above.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or
Relationship With Respect to Securities of the Issuer.
Under the terms of the Stock Issuance Agreement (filed as
Exhibit 1) the number of shares is subject to adjustment at December 31, 1997
based on the then current market price of the Common Stock of the Issuer.
Item 7. Materials to be Filed as Exhibits.
Exhibit 1. Stock Issuance Agreement dated as of
December 31, 1996.
<PAGE> 6
Page 5 of 5 Pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, the undersigned certifies that the information set forth in the
Statement is true, correct and complete.
DATED: January 10, 1997
SMITHKLINE BEECHAM PROPERTIES, LTD.
By: Donald F. Parman
--------------------------------
Donald F. Parman
Secretary
<PAGE> 1
Exhibit 1 to Schedule 13D
Connective Therapeutics, Inc.
Filer: SmithKline Beecham
Properties, Ltd.
STOCK ISSUANCE AGREEMENT
This STOCK ISSUANCE AGREEMENT dated as of December 31, 1996 is between
SmithKline Beecham Properties, Inc., a Delaware corporation ("SB"), and
Connective Therapeutics, Inc., a Delaware corporation (the "Company").
WHEREAS, the Company and SB have entered into an Asset Purchase
Agreement dated December 2, 1996 (the "Asset Purchase Agreement") pursuant to
which the Company is acquiring from SB all rights to a certain pharmaceutical
product, Ridaura, in exchange for cash and shares of the Company's common
stock;
WHEREAS, pursuant to the equity component of the Ridaura acquisition,
the Company has agreed to issue to SB shares of its common stock, par value
$0.001 per share (the "Common Stock"), which issuance shall constitute an
investment in the Company of Nine Million Dollars ($9,000,000) upon the Initial
Closing Date (as defined in Section 2.2(a)), subject to certain potential
adjustments and other terms and conditions contained herein.
NOW THEREFORE, the parties hereto agree as follows:
ARTICLE 1
DEFINITIONS
1.1 Definitions. (a) The following terms, as used herein, have
the following meanings:
"Affiliate" of an entity means, for so long as one of the
following relationships is maintained, any corporation or other business entity
controlled by, controlling, or under common control with another entity, with
"control" meaning direct or indirect beneficial ownership of more than fifty
percent (50%) of the voting stock of such corporation, or more than a fifty
percent (50%) interest in the decision-making authority of such other
unincorporated business entity.
"HSR Act" means the Hart-Scott-Rodino Antitrust Improvements
Act of 1976, as amended.
"Material Adverse Effect" means a material adverse effect on
the condition (financial or otherwise), business, assets, results of operations
or prospects of the Company, considered as a whole.
"1933 Act" means the Securities Act of 1933, as amended, and
the rules and regulations promulgated thereunder.
"1934 Act" means the Securities Exchange Act of 1934, as
amended, and the rules and regulations promulgated thereunder.
<PAGE> 2
"Person" means an individual, corporation, partnership,
association, trust or other entity or organization, including a government or
political subdivision or an agency or instrumentality thereof.
"Register," "Registered," and "Registration" refer to a
registration effected by preparing and filing a registration statement or
similar document in compliance with the 1933 Act, and the declaration or
ordering of effectiveness of such registration statement or document.
"Registrable Securities" means (i) the Shares, and (ii) any
other shares of Common Stock of the Company issued as (or issuable upon the
conversion or exercise of any warrant, right or other security which is issued
as) a dividend or other distribution with respect to, or in exchange for or in
replacement of, the Shares; provided, however, that the foregoing definition
shall exclude in all cases any Registrable Securities sold by SB in a
transaction in which its rights under this Agreement are not assigned.
Notwithstanding the foregoing, Common Stock or other securities shall only be
treated as Registrable Securities if and so long as they have not been (A) sold
to or through a broker or dealer or underwriter in a public distribution or a
public securities transaction, or (B) sold in a transaction exempt from the
registration and prospectus delivery requirements of the 1933 Act under Section
4(1) thereof so that all transfer restrictions, and restrictive legends with
respect thereto, if any, are removed upon the consummation of such sale.
"Registrable Securities then outstanding" shall be determined
by the number of shares of Common Stock outstanding which are Registrable
Securities.
"Form S-3" means such form under the 1933 Act as in effect on
the date hereof or any successor form under the 1933 Act.
"SEC" means the Securities and Exchange Commission.
"Shares" means the Initial Issuance Shares and the Second
Issuance Shares.
(b) In addition, each of the following terms is defined
in the Section set forth opposite such term:
<TABLE>
<CAPTION>
Term Section
---- -------
<S> <C>
Asset Purchase Agreement Recitals
Common Stock Recitals
Initial Closing 2.2(a)
Initial Closing Date 2.2(a)
Initial Price 2.1(a)
Initial Issuance 2.1(a)
Initial Issuance Shares 2.1(a)
Second Closing 2.2(b)
Second Closing Date 2.2(b)
Second Issuance 2.1(b)
Second Issuance Shares 2.1(b)
</TABLE>
-2-
<PAGE> 3
ARTICLE 2
ISSUANCE OF SHARES
2.1 Issuance of Shares. Upon the terms and subject to the
conditions of this Agreement, the Company agrees to issue to SB and SB agrees
to acquire from the Company, the Shares as follows:
(a) Initial Issuance. On the Initial Closing Date, the
Company shall issue to SB shares of Common Stock (the "Initial Issuance
Shares") (the number of which shall be rounded to the nearest whole number) at
a price (the "Initial Price"), each as shall be calculated as follows:
Initial Price = Two (2) times the
average daily closing price
for the Company's Common
Stock for the twenty (20)
trading days immediately
preceding (but not including)
the third trading day before
the Initial Closing Date, as
reported on the NASDAQ
National Market System.
$9,000,000
-------------
Initial Issuance Shares = Initial Price
Such issuance shall be referred to hereinafter as the
"Initial Issuance."
(b) Adjustments on Second Closing Date.
(i) Second Issuance. If on the Second Closing
Date, the aggregate market value of the Initial Issuance Shares is less than
$9,000,000 (based upon the average daily closing price per share for the
Company's Common Stock for the twenty (20) trading days immediately preceding
(but not including) the third trading day before the Second Closing Date, as
reported on the NASDAQ National Market System), then the Company shall issue
that number of additional shares of its Common Stock (the "Second Issuance
Shares") sufficient to bring such aggregate market value of the Shares to
$9,000,000. Such issuance shall be referred to hereinafter as the "Second
Issuance."
(ii) Redemption of Shares. If on the Second
Closing Date, the aggregate market value of the Initial Issuance Shares is
greater than $9,000,000 (based upon the average daily closing price per share
for the Company's Common Stock for the twenty (20) trading days immediately
preceding (but not including) the third trading day before the Second Closing
Date, as reported on the NASDAQ National Market System), then the Company shall
have the right, but not the obligation, to redeem from SB at a price of $0.01
per share that number of the Initial Issuance Shares sufficient to reduce such
aggregate market value of the remaining Initial Issuance Shares to $9,000,000.
In such event, the Company shall deliver to SB at the Second Closing by check
or wire transfer the aggregate redemption price for the excess portion of the
Initial Issuance Shares, and SB will deliver for cancellation the stock
certificate representing the original Initial Issuance Shares (which the
Company will replace as soon as
-3-
<PAGE> 4
practicable thereafter with a stock certificate representing the remaining
portion of the Initial Issuance Shares after the redemption set forth above).
(iii) Other Valuations. In the event that neither
Section 2.1(b)(i) nor Section 2.1(b)(ii) is applicable, then there shall be no
Second Issuance nor any redemption of the Initial Issuance Shares at the Second
Closing.
(c) Approval of the Company's Stockholders. In all events
the sum of the Initial Issuance Shares and the Second Issuance Shares (if any)
shall be not greater than 19.9% of the outstanding Common Stock of the Company
prior to their issuance. In the event that such sum of the Shares is greater
than 19.9% of the outstanding Common Stock of the Company prior to their
issuance, then, at SKB's discretion, (i) the Second Issuance Shares shall be
reduced until such sum of the Shares is equal to 19.9% of the outstanding
Common Stock of the Company, (ii) the issuance of the Second Issuance Shares
shall be subject to, and conditioned upon, approval of the issuance of the
Shares by the Company's Stockholders or (iii) the Second Closing shall be
delayed until the approval of the issuance of the Shares by the Company's
Stockholders. In the event that SB elects to proceed under clause (ii) or
(iii) above, and such stockholder approval is not obtained by December 3, 1998,
then the Company shall be obligated to pay SB in cash the value of the Second
Issuance Shares that would have been issued on the originally-scheduled Second
Closing Date but for this subsection (based upon the average daily closing
price per share for the Company's Common Stock for the twenty (20) trading days
immediately preceding (but not including) the third trading day before the
originally-scheduled Second Closing Date, as reported on the NASDAQ National
Market System). Such payment obligation shall be secured by certain of the
assets acquired by the Company from SB pursuant to a Security Agreement of even
date herewith.
2.2 Closing Dates.
(a) Initial Closing Date. The closing of the acquisition
and issuance of the Initial Issuance Shares (the "Initial Closing") shall be
held at 4:00 p.m. Pacific Standard time on the date (the "Initial Closing
Date") upon which the conditions set forth in Sections 6.1 and 6.2 have been
satisfied or waived, or at such other time or date as the Company and SB may
agree in writing. The parties presently expect that the Initial Closing Date
will be the closing date for the Asset Purchase Agreement, currently scheduled
for December 31, 1996.
(b) Second Closing Date. The closing of the issuance of
the Second Issuance Shares or the redemption of the Initial Issuance Shares
pursuant to Section 2.1(b) (the "Second Closing") shall be held at 4:00 p.m.
Pacific Standard time on that date which is twelve (12) calendar months after
the Initial Closing Date (the "Second Closing Date") and which is following the
satisfaction or waiver of the conditions set forth in Sections 6.3 and 6.4, or
at such other time or date as the Company and SB may agree in writing.
(c) Location. The Initial Closing and the Second Closing
shall be held at the offices of SB at One Franklin Plaza, Philadelphia,
Pennsylvania 19102 or at such other place as the Company and SB may agree in
writing.
-4-
<PAGE> 5
(d) Acceleration of Second Closing Date. In the event of
the sale by the Company of all or substantially all of its assets or the
acquisition of the Company by another entity by means of merger or other
transaction as a result of which shareholders of the Company immediately prior
to such acquisition possess a minority of the voting power of the acquiring
entity immediately following such acquisition (an "Acquisition"), then the
Second Closing Date shall be accelerated to a date mutually acceptable to the
Company and SB, which date in no event shall be later than one (1) day prior to
the closing of such Acquisition.
2.3 Delivery. Subject to the terms and conditions of this
Agreement, at the Initial Closing and the Second Closing, as the case may be,
or as soon as practicable thereafter, the Company will deliver to SB stock
certificates representing the number of Shares subject to issuance hereunder.
One (1) business day prior to the Initial Closing Date, the Company shall
provide SB with a letter from the Chief Financial Officer of the Company
specifying the calculation of the Initial Price and the number of Initial
Issuance Shares to be issued at the Initial Closing. One (1) business day
prior to the Second Closing Date, the Company shall provide SB with a letter
from the Chief Financial Officer of the Company specifying the calculation of
the number of Second Issuance Shares (if any) to be issued at the Second
Closing, the number of Initial Issuance Shares (if any) to be redeemed at the
Second Closing, or the fact that no issuance or redemption will occur at the
Second Closing pursuant to Section 2.1(b)(iii).
2.4 Restriction on Transfer. SB hereby agrees that, without the
prior written consent of the Company, it will not, during the period commencing
on the Initial Closing Date and ending on the Second Closing Date, (1) offer,
pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to
purchase, or otherwise transfer or dispose of, directly or indirectly, any
Shares or (2) enter into any swap or other arrangement that transfers to
another, in whole or in part, any of the economic consequences of ownership of
the Shares, whether any such transaction described in clause (1) or (2) above
is to be settled by delivery of the Shares or such other securities, in cash or
otherwise.
ARTICLE 3
REGISTRATION RIGHTS AND SALE OF SHARES
3.1 Form S-3 Registration. Unless otherwise requested by SB, the
Company will use its best efforts to prepare and file (and on or before the
Second Closing Date, effect) a registration statement on Form S-3 that
contemplates a distribution of securities on a delayed or continuous basis
pursuant to Rule 415 under the 1933 Act and any related qualification or
compliance with respect to all of the Registrable Securities; provided,
however, that the Company shall not be obligated to effect any such
registration, qualification or compliance: (1) if Form S-3 is not available
for such offering by SB other than by reason of the Company's action or
inaction; or (2) if the Company shall furnish to SB a certificate signed by the
President of the Company stating that in the good faith judgment of the
Company, it would be seriously detrimental to the Company and its stockholders
for such Form S-3 Registration to be effected at such time, in which event the
Company shall have the right to defer the filing or effectiveness of the Form
S-3 registration statement for a period of time deemed necessary by the
Company, but in any event not to exceed ninety (90) days.
-5-
<PAGE> 6
3.2 Obligations of the Company. When required under this Article
3 to effect the registration of the Registrable Securities, the Company shall,
as expeditiously as reasonably possible:
(a) Use its best efforts to cause such registration
statement to become effective on or before the Second Closing Date, and, upon
the request of SB, keep such registration statement effective for up to two (2)
years and update such registration statement during such two-year period;
provided, however, if the Company shall furnish to SB a certificate signed by
the President of the Company stating that in the good faith judgment of the
Company, it would be seriously detrimental to the Company and its stockholders
for such registration statement to remain effective, the Company shall have the
right to suspend the effectiveness of the registration statement for a period
of time deemed necessary by the Company, but in any event not to exceed ninety
(90) days.
(b) Furnish to SB such numbers of copies of a prospectus,
including a preliminary prospectus, in conformity with the requirements of the
1933 Act, and such other documents as it may reasonably request in order to
facilitate the disposition of Registrable Securities.
(c) Use its best efforts to register and qualify the
securities covered by such registration statement under such other securities
or Blue Sky laws of such jurisdictions as shall be reasonably requested by SB,
provided that the Company shall not be required in connection therewith or as a
condition thereto to qualify to do business or to file a general consent to
service of process in any such states or jurisdictions.
3.3 Furnish Information. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Article 3 with
respect to the Registrable Securities that SB shall furnish to the Company such
information regarding itself, the Registrable Securities held by it, and the
intended method of disposition of such securities as shall be required to
effect the registration of the Registrable Securities.
3.4 Expenses of Registration. All expenses other than
underwriting discounts and commissions incurred in connection with
registrations, filings or qualifications pursuant to this Article 3, including
(without limitation) all registration, filing and qualification fees, printers'
and accounting fees, fees and disbursements of counsel for the Company, and the
reasonable fees and disbursements of one counsel for SB shall be borne by the
Company.
3.5 Limitation on Sale of Shares. SB will notify the Company at
least two trading days in advance of any proposed sale or other transfer of any
Registrable Securities. SB and the Company agree and acknowledge that it is in
their mutual interest that disposition of the Registrable Securities be
accomplished in a manner that does not disrupt or undermine the trading market
for the Company's common stock on the NASDAQ National Market System, and the
parties will work together to explore methods of disposition in order to
achieve such goal. SB will also consider in good faith any request by the
Company to delay such sale or transfer for a reasonable time or to arrange such
sale or transfer through an underwriter or market maker approved by the
Company.
-6-
<PAGE> 7
3.6 Indemnification. In the event any Registrable Securities are
included in a registration statement under this Article 3:
(a) To the extent permitted by law, the Company will
indemnify and hold harmless SB, any underwriter (as defined in the 1933 Act)
for SB and each person, if any, who controls SB or such underwriter within the
meaning of the 1933 Act or the 1934 Act, against any losses, claims, damages,
or liabilities (joint or several) to which they may become subject under the
1933 Act, the 1934 Act or other federal or state law, insofar as such losses,
claims, damages, or liabilities (or actions in respect thereof) arise out of or
are based upon any of the following statements, omissions or violations
(collectively a "Violation"): (i) any untrue statement or alleged untrue
statement of a material fact contained in such registration statement,
including any preliminary prospectus or final prospectus contained therein or
any amendments or supplements thereto, (ii) the omission or alleged omission to
state therein a material fact required to be stated therein, or necessary to
make the statements therein not misleading, or (iii) any violation or alleged
violation by the Company of the 1933 Act, the 1934 Act, any state securities
law or any rule or regulation promulgated under the 1933 Act, the 1934 Act or
any state securities law; and the Company will pay to SB and each such
underwriter or controlling person, as incurred, any legal or other expenses
reasonably incurred by them in connection with investigating or defending any
such loss, claim, damage, liability, or action; provided, however, that the
indemnity agreement contained in this subsection 3.6(a) shall not apply to
amounts paid in settlement of any such loss, claim, damage, liability, or
action if such settlement is effected without the consent of the Company (which
consent shall not be unreasonably withheld), nor shall the Company be liable in
any such case for any such loss, claim, damage, liability, or action to the
extent that it arises out of or is based upon a Violation which occurs in
reliance upon and in conformity with written information furnished expressly
for use in connection with such registration by SB or any such underwriter or
controlling person.
(b) To the extent permitted by law, SB will indemnify and hold
harmless the Company, each of its directors, each of its officers who has
signed the registration statement, each person, if any, who controls the
Company within the meaning of the 1933 Act, any underwriter, any other person
selling securities in such registration statement and any controlling person of
any such underwriter or other person, against any losses, claims, damages, or
liabilities (joint or several) to which any of the foregoing persons may become
subject, under the 1933 Act, the 1934 Act or other federal or state law,
insofar as such losses, claims, damages, or liabilities (or actions in respect
thereto) arise out of or are based upon any Violation, in each case to the
extent (and only to the extent) that such Violation occurs in reliance upon and
in conformity with written information furnished by SB expressly for use in
connection with such registration; and SB will pay, as incurred, any legal or
other expenses reasonably incurred by any person intended to be indemnified
pursuant to this subsection 3.6(b), in connection with investigating or
defending any such loss, claim, damage, liability, or action; provided,
however, that the indemnity agreement contained in this subsection 3.6(b) shall
not apply to amounts paid in settlement of any such loss, claim, damage,
liability or action if such settlement is effected without the consent of SB,
which consent shall not be unreasonably withheld. Notwithstanding the
foregoing, in no event shall SB's total indemnification obligation exceed the
aggregate amounts SB has received from the sale of the Shares pursuant to the
registration statement filed under this Article 3.
-7-
<PAGE> 8
(c) Promptly after receipt by an indemnified party under
this Section 3.6 of notice of the commencement of any action (including any
governmental action), such indemnified party will, if a claim in respect
thereof is to be made against any indemnifying party under this Section 3.6,
deliver to the indemnifying party a written notice of the commencement thereof
and the indemnifying party shall have the right to participate in, and, to the
extent the indemnifying party so desires, jointly with any other indemnifying
party similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party
(together with all other indemnified parties which may be represented without
conflict by one counsel) shall have the right to retain one separate counsel,
with the reasonable fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing
interests between such indemnified party and any other party represented by
such counsel in such proceeding. The failure to deliver written notice to the
indemnifying party within a reasonable time of the commencement of any such
action, if prejudicial to its ability to defend such action, shall relieve such
indemnifying party of any liability to the indemnified party under this Section
3.6, but the omission so to deliver written notice to the indemnifying party
will not relieve it of any liability that it may have to any indemnified party
otherwise than under this Section 3.6.
(d) If the indemnification provided for in this Section
3.6 is held by a court of competent jurisdiction to be unavailable to an
indemnified party with respect to any loss, liability, claim, damage, or
expense referred to therein, then the indemnifying party, in lieu of
indemnifying such indemnified party hereunder, shall contribute to the amount
paid or payable by such indemnified party as a result of such loss, liability,
claim, damage, or expense in such proportion as is appropriate to reflect the
relative fault of the indemnifying party on the one hand and of the indemnified
party on the other in connection with the statements or omissions that resulted
in such loss, liability, claim, damage, or expense as well as any other
relevant equitable considerations. The relative fault of the indemnifying
party and of the indemnified party shall be determined by reference to, among
other things, whether the untrue or alleged untrue statement of a material fact
or the omission to state a material fact relates to information supplied by the
indemnifying party or by the indemnified party and the parties' relative
intent, knowledge, access to information, and opportunity to correct or prevent
such statement or omission.
(e) Notwithstanding the foregoing, to the extent that the
provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are
in conflict with the foregoing provisions, the provisions in the underwriting
agreement shall control.
(f) The obligations of the Company and SB under this
Section 3.6 shall survive the completion of any offering of Registrable
Securities in a registration statement under this Article 3, and otherwise.
3.7 Assignment of Registration Rights. The rights to cause the
Company to register Registrable Securities pursuant to this Article 3 may not
be assigned by SB without the Company's prior written consent. Any such
assignment consented to by the Company shall be
-8-
<PAGE> 9
effective only if immediately following such transfer the further disposition
of such securities by the transferee or assignee is restricted under the 1933
Act.
3.8 Termination of Registration Rights. SB shall not be entitled
to exercise any right provided for in this Article 3, and the Company shall
have no further obligations under this Article 3, after such time as Rule 144
or another similar exemption under the 1933 Act is available for the sale of
all of SKB's shares during a three (3) month period without registration.
ARTICLE 4
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
The Company represents and warrants to SB as of the date hereof that,
except as set forth on the attached Schedule of Exceptions:
4.1 Corporate Existence and Power. The Company is a corporation
duly incorporated, validly existing and in good standing under the laws of
Delaware.
4.2 Corporate Authorization. The execution, delivery and
performance by the Company of this Agreement has been duly authorized by all
necessary corporate action on the part of the Company. This Agreement
constitutes a valid and binding agreement of the Company enforceable in
accordance with its terms, except as (i) the enforceability hereof and thereof
may be limited by bankruptcy, insolvency, moratorium or other similar laws
affecting the enforcement of creditors' rights generally, (ii) the availability
of equitable remedies (e.g., specific performance, injunctive relief, and other
equitable remedies) may be limited by equitable principles of general
applicability, (iii) to the extent the indemnification provisions contained in
this Agreement may be limited by applicable federal or state securities law;
and (iv) that no representation is made regarding the effect of laws relating
to competition, antitrust, intellectual property or misuse or the effect of
SB's or third parties' intellectual property rights.
4.3 Governmental Authorization. The execution, delivery and
performance by the Company of this Agreement will not require any action by, or
filing with, any governmental body, agency, or official other than (i)
compliance with any applicable requirements of the HSR Act and (ii) compliance
with any applicable requirements of the 1933 Act, the 1934 Act and state Blue
Sky laws.
4.4 Non-Contravention. The execution, delivery and performance by
the Company of this Agreement does not (i) violate the certificate of
incorporation or bylaws of the Company, (ii) assuming compliance with the
matters referred to in Section 4.3, violate any material applicable law, rule,
regulation, judgment, injunction, order or decree known to it, or (iii) require
any consent or other action by any Person under, constitute a material default
under, or give rise to any material right of termination, cancellation or
acceleration of any material right or obligation of the Company to a loss of
any material benefit to which the Company is entitled under, any material
written agreement or other material written instrument binding upon the Company
or any material license, franchise, permit or other similar authorization held
by the Company.
-9-
<PAGE> 10
4.5 Validity of Shares. The Shares, when issued, sold and
delivered in accordance with the terms and for the consideration set forth in
this Agreement, will be duly and validly issued, fully paid and nonassessable.
4.6 SEC Filings. The Company has delivered to SB or its counsel
the Company's (i) Prospectus dated January 31, 1996 for its initial public
offering, (ii) quarterly reports on Form 10-Q for its fiscal quarters ended
March 31, 1996, June 30, 1996 and September 30, 1996, and (iii) all of its
other reports, statements and registration statements (without exhibits) filed
with the SEC since January 31, 1996, except for filings pursuant to Rule 144 of
the 1933 Act and Sections 13(d) and 16(b) of the 1934 Act.
4.7 Absence of Certain Changes. Since September 30, 1996 and
except as contemplated by this Agreement or disclosed in any filing with the
SEC pursuant to the 1934 Act, and except as disclosed to SB, the business of
the Company has been conducted in the ordinary course consistent with past
practices and there has not been any event, occurrence, development or state of
circumstances or facts which, individually or in the aggregate, has had a
Material Adverse Effect.
ARTICLE 5
REPRESENTATIONS AND WARRANTIES OF SB
5.1 Representations and Warranties. SB hereby represents and
warrants to the Company as of the date hereof as follows:
(a) SB is a corporation duly organized, validly existing,
authorized to exercise all its corporate powers, rights and privileges, and in
good standing under the laws of Pennsylvania.
(b) SB has taken all necessary corporate action necessary
for the execution, delivery and performance of this Agreement and the
consummation of the transactions contemplated hereby, and this Agreement
constitutes a valid and legally binding obligation of SB enforceable in
accordance with its terms.
(c) The execution, delivery and performance of this
Agreement by SB will not result in any violation of, be in conflict with, or
constitute a default under, with or without the passage of time or the giving
of notice: (i) any provision of SB's charter or bylaws or similar
organizational document of SB; (ii) any provision of any judgment, decree or
order to which SB is a party or by which it is bound; (iii) any contract,
obligation or commitment to which SB is a party or by which it is bound; or
(iv) any statute, rule or governmental regulation applicable to SB.
(d) The execution, delivery and performance of this
Agreement by SB will not require any consent, approval, authorization or permit
of, or filing with or without notification to, any governmental or regulatory
authority, United States or foreign, except for applicable requirements, if
any, of the 1933 Act or 1934 Act, Blue Sky Laws, and HSR Act requirements.
-10-
<PAGE> 11
5.2 Purchase of Shares for Investment. SB acknowledges that the
Shares have not been registered under the 1933 Act or any state securities laws
and that the Company has no present intention of registering the Shares, except
as provided in Article 3 hereof. SB represents and warrants that it is
acquiring the Shares for investment purposes only, and not as a nominee or
agent, and not with a view to, or for resale or redistribution of such Shares
in connection with, any public offering or distribution thereof, except as
provided in Article 3 hereof. By executing this Agreement, SB further
represents that it does not have any contract, undertaking, agreement or
arrangement with any person to sell, transfer or grant participations to such
person or to any third person, with respect to any of the Shares.
5.3 Restricted Securities. SB understands that the Shares may not
be sold, transferred, or otherwise disposed of without registration under the
1933 Act or an exemption therefrom, and that in the absence of an effective
registration statement covering the Shares or an available exemption from
registration under the 1933 Act, the Shares must be held indefinitely. In
particular, SB is aware that the Shares may not be sold pursuant to Rule 144
promulgated under the 1933 Act unless the conditions of that Rule are met.
5.4 Legend. Each certificate representing the Shares shall be
endorsed with the following legend:
THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND
MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS THERE IS AN
EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT COVERING SUCH
SECURITIES, THE TRANSFER IS MADE IN COMPLIANCE WITH RULE 144
PROMULGATED UNDER SUCH ACT, OR THE COMPANY RECEIVES AN OPINION
OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY STATING THAT
SUCH SALE, TRANSFER OR ASSIGNMENT IS EXEMPT FROM THE
REGISTRATION AND DELIVERY REQUIREMENTS OF SUCH ACT.
The Company need not register a transfer of any Shares and may
instruct its transfer agent not to register the transfer of the Shares, unless
the conditions specified in the foregoing legend are satisfied.
ARTICLE 6
CONDITIONS TO CLOSINGS
6.1 Conditions to Initial Issuance Obligations of SB. The
obligation of SB to consummate the Initial Issuance is subject to the
satisfaction or SB's waiver, on or prior to the Initial Closing Date, of each
of the following conditions:
(a) The representations and warranties made by the
Company in Article 4 shall be true and correct when made, and shall be true and
correct on the Initial Closing Date with the same force and effect as if they
had been made on and as of each of such dates and the Company
-11-
<PAGE> 12
shall have performed all covenants, obligations and conditions required to be
performed or observed by the Company on or prior to the Initial Closing Date,
or such performance shall have expressly waived by SB in writing.
(b) The Company and SB shall have obtained all consents
(including all governmental or regulatory consents, approvals or authorizations
required in connection with the valid execution and delivery of this
Agreement), permits and waivers necessary or appropriate for consummation of
the transactions contemplated by the Initial Issuance under this Agreement.
(c) No Delaware, U.S. or U.S. state governmental
authority or other agency or commission or Delaware, U.S. or U.S. state court
of competent jurisdiction shall have enacted, issued, promulgated, enforced, or
entered any law, rule, regulation, executive order, decree, injunction or other
order which is then in effect and has the effect of making illegal the issuance
of the Initial Issuance Shares to SB or otherwise preventing the consummation
of any of the transactions contemplated under this Agreement.
(d) Any waiting period (including any extension thereof)
applicable to the consummation of the issuance of the Initial Issuance Shares
under the HSR Act shall have expired or been terminated early.
(e) The Company and SB shall have executed and delivered
the Asset Purchase Agreement.
(f) There shall be no temporary restraining order,
preliminary injunction or permanent injunction or other order preventing the
consummation of the Initial Issuance issued by any court which remains in
effect, no litigation seeking the issuance of such an order or injunction and
no claims or actions threatened or pending which have a reasonably likely
prospect of resulting in such order or injunction preventing the consummation
of the Initial Issuance.
(g) The Company shall not be in material breach of the
Asset Purchase Agreement.
6.2 Conditions to Initial Issuance Obligations of the Company.
The obligations of the Company to issue the Initial Issuance Shares is subject
to the satisfaction or the Company's waiver, on or prior to the Initial Closing
Date, of each of the following conditions:
(a) The representations and warranties made by SB in
Article 5 shall be true and correct when made, and shall be true and correct on
the Initial Closing Date with the same force and effect as if they had been
made on and as of such date and SB shall have performed all covenants,
obligations and conditions required to be performed or observed by SB on or
prior to the Initial Closing Date or such performance shall have been expressly
waived by the Company in writing.
(b) The Company and SB shall have executed and delivered
the Asset Purchase Agreement, which shall remain in full force and effect.
-12-
<PAGE> 13
(c) The Company and SB shall have obtained all consents
(including all third party and governmental or regulatory consents, approvals
or authorizations required in connection with the valid execution and delivery
of this Agreement), permits and waivers necessary or appropriate for
consummation of the transactions contemplated by the Initial Issuance under
this Agreement.
(d) No Delaware, U.S. or U.S. state governmental
authority or other agency or commission or Delaware, U.S. or U.S. state court
of competent jurisdiction, shall have enacted, issued, promulgated, enforced,
or entered any law, rule, regulation, executive order, decree, injunction or
other order which is then in effect and has the effect of making illegal the
issuance of the Initial Issuance Shares to SB or otherwise preventing the
consummation of any of the transactions contemplated under this Agreement.
(e) Any waiting period (including any extension thereof)
applicable to the consummation of the sale of the Initial Issuance Shares under
the HSR Act shall have expired or been terminated early.
6.3 Conditions to Second Closing Obligations of SB. The
obligation of SB to consummate the Second Closing is subject to the
satisfaction or SB's waiver, on or prior to the Second Closing Date, of each of
the following conditions:
(a) The representations and warranties made by the
Company in Sections 4.1, 4.2, and 4.4 shall be true and correct on the Second
Closing Date with the same force and effect as if they had been made on and as
of such date, and the Company shall have performed all covenants, obligations
and conditions required to be performed or observed by it on or prior to the
Second Closing Date.
(b) The Company and SB shall have obtained all consents
(including all governmental or regulatory consents, approvals or authorizations
required in connection with the valid execution and delivery of this
Agreement), permits and waivers necessary or appropriate for consummation of
the transactions contemplated by the Second Closing under this Agreement.
(c) No Delaware, U.S. or U.S. state governmental
authority or other agency or commission or Delaware, U.S. or U.S. state court
of competent jurisdiction shall have enacted, issued, promulgated, enforced, or
entered any law, rule, regulation, executive order, decree, injunction or other
order which is then in effect and has the effect of making illegal the issuance
of the Second Issuance Shares (if any) to SB or otherwise preventing the
consummation of any of the transactions contemplated under this Agreement.
(d) The Company shall have delivered a certificate to SB
as set forth in Section 2.3.
(e) There shall be no temporary restraining order,
preliminary injunction or permanent injunction or other order preventing the
consummation of the Second Closing issued by any court which remains in effect,
no litigation seeking the issuance of such an order or
-13-
<PAGE> 14
injunction and no claims or actions threatened or pending which have a
reasonably likely prospect of resulting in such order or injunction preventing
the consummation of the Second Closing.
6.4 Conditions to Second Closing Obligations of the Company. The
obligations of the Company to issue the Second Issuance Shares (if any) is
subject to the satisfaction or the Company's waiver, on or prior to the Second
Closing Date, of each of the following conditions:
(a) The representations and warranties made by SB in
Article 5 shall be true and correct when made, and shall be true and correct on
the Second Closing Date with the same force and effect as if they had been made
on and as of such date.
(b) The Company shall have obtained all consents
(including all third party and governmental or regulatory consents, approvals
or authorizations required in connection with the valid execution and delivery
of this Agreement), permits and waivers necessary or appropriate for
consummation of the transactions contemplated by the Second Closing under this
Agreement.
(c) No Delaware, U.S. or U.S. state governmental
authority or other agency or commission or Delaware, U.S. or U.S. state court
of competent jurisdiction shall have enacted, issued, promulgated, enforced, or
entered any law, rule, regulation, executive order, decree, injunction or other
order which is then in effect and has the effect of making illegal the issuance
of the Second Issuance Shares (if any) to SB or otherwise preventing the
consummation of any of the transactions contemplated under this Agreement.
(d) At the time of the closing on the Second Closing
Date, the issuance of the Shares to SB shall be legally permitted by all laws
and regulations to which SB and the Company are subject.
(e) There shall be no temporary restraining order,
preliminary injunction or permanent injunction or other order preventing the
consummation of the Second Closing issued by any court which remains in effect,
no litigation seeking the issuance of such an order or injunction and no claims
or actions threatened or pending which have a reasonably likely prospect of
resulting in such order or injunction preventing the consummation of the Second
Closing.
ARTICLE 7
COVENANTS OF THE COMPANY
The Company agrees that:
7.1 Access to Information. From the date hereof until the Initial
Closing Date, the Company will (i) give, SB, its counsel and other authorized
representatives full access during reasonable business hours to the offices,
properties, books and records of the Company, (ii) furnish to SB, its counsel,
financial advisors, auditors and other authorized representatives such
financial and operating data and other information relating to the Company as
such Persons may reasonably request and (iii) instruct the employees, counsel
and financial advisors of the Company to cooperate with SB's reasonable
requests in its investigation of the Company. No investigation by SB or other
information received by SB shall operate as a waiver or otherwise
-14-
<PAGE> 15
affect any representation, warranty or agreement given or made by the Company
hereunder. Notwithstanding the foregoing, SB shall not have access to
personnel records of the Company relating to individual performance or
evaluation records, medical histories or other information which in the
Company's good faith opinion is sensitive or the disclosure of which could
subject the Company to risk of liability.
7.2 Reservation of Shares. The Company shall at all times reserve
and keep available out of its authorized but unissued shares of Common Stock
such number of shares of Common Stock as shall be sufficient to complete the
issuance of the Shares under this Agreement.
7.3 Maintenance of Registration under the 1934 Act during Pendency
of S-3 Registration Statement. The Company shall use its best efforts to
maintain the effectiveness of the registration of its Common Stock under
Section 12(g) of the 1934 Act during the effectiveness of the registration
statement filed under Article 3.
ARTICLE 8
COVENANTS OF SB
The SB covenants and agrees that:
8.1 Confidentiality. SB and its Affiliates will hold, and will
use all reasonable business efforts to cause their respective officers,
directors, employees, accountants, counsel, consultants, advisors and agents to
hold, in confidence, all confidential documents and information concerning the
Company furnished to SB or its Affiliates in connection with the transactions
contemplated by this Agreement and the Asset Purchase Agreement, except to the
extent that such information can be shown to have been (i) previously known on
a nonconfidential basis by SB, (ii) in the public domain through no fault of SB
or (iii) later lawfully acquired by SB from sources other than the Company;
provided that SB may disclose such information to its officers, directors,
employees, accountants, counsel, consultants, advisors and agents in connection
with the transactions contemplated by this Agreement and the Asset Purchase
Agreement so long as (a) such disclosure is necessary for the evaluation and
consummation of the transactions contemplated by this Agreement and the Asset
Purchase Agreement and (b) such Persons are informed by SB of the confidential
nature of such information and are bound in writing by SB to treat such
information confidentially. SB and its Affiliates shall exercise at least the
same care with respect to such information as they would take to preserve the
confidentiality of their own similar information. If this Agreement is
terminated, SB and its Affiliates use all reasonable business efforts to cause
their respective officers, directors, employees, accountants, counsel,
consultants, advisors and agents to, destroy or deliver to the Company, upon
request, all documents and other materials, and all copies thereof, obtained by
SB or its Affiliates or on their behalf from the Company in connection with
this Agreement or the Asset Purchase Agreement that are subject to such
confidence. This Section 8.1 shall survive any termination of this Agreement.
8.2 1934 Act Filings. SB agrees and acknowledges that it shall
have sole responsibility for making any filings with the SEC pursuant to
Sections 13(d) and 16(b) of the 1934 Act as a result of its acquisition of the
Shares and any future retention or transfer thereof.
-15-
<PAGE> 16
ARTICLE 9
COVENANTS OF SB AND THE COMPANY
SB and the Company agree that:
9.1 Best Efforts. Subject to the terms and conditions of this
Agreement, SB and the Company will use their best efforts to take, or cause to
be taken, all actions and to do, or cause to be done, all things necessary or
desirable under applicable laws and regulations to consummate the transactions
contemplated by this Agreement and the Asset Purchase Agreement. The Company
and SB agree to execute and deliver such other documents, certificates,
agreements and other writings and to take such other actions as may be
necessary or desirable in order to consummate or implement expeditiously the
transactions contemplated by this Agreement and the Asset Purchase Agreement.
9.2 Certain Filings. The Company and SB shall cooperate with one
another (i) in determining whether any action by or in respect of, or filing
with, any governmental body, agency, official or authority is required, or any
actions, consents, approvals or waivers are required to be obtained from
parties to any material contracts, in connection with the consummation of the
transactions contemplated by this Agreement and the Asset Purchase Agreement
(including without limitation any filings or other actions required under the
HSR Act) and (ii) in taking such actions or making any such filings, furnishing
information required in connection therewith and seeking timely to obtain any
such actions, consents, approvals or waivers.
9.3 Public Announcements. The parties agree to consult with each
other before issuing any press release or making any public statement with
respect to this Agreement or the Asset Purchase Agreement or the transactions
contemplated hereby or thereby and, except as may be required by applicable law
or any listing agreement with any national securities exchange or market, will
not issue any such press release or make any such public statement prior to
such consultation.
ARTICLE 10
SURVIVAL; INDEMNIFICATION
10.1 Survival. The covenants, agreements, representations and
warranties of the parties hereto contained in this Agreement or in any
certificate or other writing delivered pursuant hereto or in connection
herewith shall survive the Second Closing for a period of one (1) year.
ARTICLE 11
TERMINATION
11.1 Grounds for Termination. This Agreement may be terminated at
any time prior to the Initial Closing or the Second Closing, as applicable:
(i) by mutual written agreement of the Company and SB;
-16-
<PAGE> 17
(ii) by either the Company or SB if the Initial Closing
shall not have been consummated on or before January 31, 1997;
(iii) by either the Company or SB if there shall be any law
or regulation that makes consummation of the transactions contemplated hereby
illegal or otherwise prohibited or if consummation of the transactions
contemplated hereby would violate any nonappealable final order, decree or
judgment of any court or governmental body having competent jurisdiction; or
(iv) by the Company or by SB, if there has been a material
misrepresentation or breach of warranty on the part of SB (in the case of
termination by the Company) or by the Company (in the case of termination by
SB) in the representations and warranties contained herein; or any condition to
such party's obligations hereunder becomes incapable of fulfillment through no
fault of such party and is not waived by such party;
provided that the party against whom termination is sought shall be afforded
the opportunity to cure any defect until such Initial Closing Date or Second
Closing Date, as the case may be. The party desiring to terminate this
Agreement shall give notice of such termination to the other party.
11.2 Effect of Termination. If this Agreement is terminated as
permitted by Section 11.1, termination shall be without liability of either
party (or any stockholder, director, officer, employee, agent, consultant or
representative of such party) to the other party to this Agreement; provided
that if such termination shall result from the willful failure of either party
to fulfill a condition to the performance of the obligations of the other
party, failure to perform a covenant of this Agreement or breach by either
party hereto of any representation or warranty or agreement contained herein,
such party shall be fully liable for any and all damages incurred or suffered
by the other party as a result of such failure or breach. Any dispute
regarding the foregoing shall be resolved pursuant to Section 12.8 hereto. The
provisions of Section 8.1 shall survive any termination hereof pursuant to
Section 11.1 or otherwise.
ARTICLE 12
MISCELLANEOUS
12.1 Notices. All notices, requests and other communications to
any party hereunder shall be in writing (including facsimile transmission) and
shall be given,
if to SB, to:
SmithKline Beecham Pharmaceuticals
One Franklin Plaza
Philadelphia, PA 19102
Attn: Francis Molettieri
Fax: (215) 751-5509
-17-
<PAGE> 18
with a copy to:
SmithKline Beecham Corporation
One Franklin Plaza
Philadelphia, PA 19102
Attn: Corporate Legal
Fax: (215) 751-5349
if to the Company, to:
Connective Therapeutics, Inc.
3400 W. Bayshore Road
Palo Alto, CA 94303
Attention: Chief Executive Officer
Fax: (415) 843-2899
with a copy to:
Venture Law Group
2800 Sand Hill Road
Menlo Park, CA 94025
Attention: Joshua L. Green
Fax: (415) 233-8386
All such notices, requests and other communications shall be
deemed received on the date of receipt by the recipient thereof if received
prior to 5 p.m. in the place of receipt and such day is a business day in the
place of receipt.
Otherwise, any such notice, request or communication shall be
deemed not to have been received until the next succeeding business day in the
place of receipt.
12.2 Amendments and Waivers. (a) Any provision of this Agreement
may be amended or waived prior to the Closing Date if, but only if, such
amendment or waiver is in writing and is signed, in the case of an amendment,
by each party to this Agreement, or in the case of a waiver, by the party
against whom the waiver is to be effective.
(b) No failure or delay by any party in exercising any
right, power or privilege hereunder shall operate as a waiver thereof nor shall
any single or partial exercise thereof preclude any other or further exercise
thereof or the exercise of any other right, power or privilege. The rights and
remedies herein provided shall be cumulative and not exclusive of any rights or
remedies provided by law.
12.3 Expenses. All costs and expenses incurred in connection with
this Agreement shall be paid by the party incurring such cost or expense.
-18-
<PAGE> 19
12.4 Successors and Assigns. The provisions of this Agreement
shall be binding upon and inure to the benefit of the parties hereto and their
respective successors and assigns; provided that no party may assign, delegate
or otherwise transfer any of its rights or obligations under this Agreement
without the consent of each other party hereto.
12.5 Governing Law. This Agreement shall be governed by and
construed in accordance with the law of the State of California, without regard
to the conflicts of law rules of such state.
12.6 Counterparts; Third Party Beneficiaries. This Agreement may
be signed in any number of counterparts, each of which shall be an original,
with the same effect as if the signatures thereto and hereto were upon the same
instrument. No provision of this Agreement is intended to confer upon any
Person other than the parties hereto any rights or remedies hereunder.
12.7 Entire Agreement. This Agreement and the Asset Purchase
Agreement constitute the entire agreement between the parties with respect to
the subject matter of this Agreement and supersedes all prior agreements and
understandings, both oral and written, between the parties with respect to the
subject matter of this Agreement. No representation, inducement, promise,
understanding, condition or warranty not set forth herein has been made or
relied upon by either party hereto.
12.8 Arbitration.
(a) Any dispute arising out of or in connection with this
Agreement shall be submitted to arbitration. The arbitration shall be
conducted according to the Commercial Arbitration Rules of the American
Arbitration Association. The place of arbitration shall be such place as may
be agreed upon by the parties or, in the absence of the parties' agreement, by
the arbitrators. Both parties shall attempt to agree upon one arbitrator, but
if they are unable to agree, each shall appoint an arbitrator and these two
shall appoint a third arbitrator. Expenses of the arbitrator(s) shall be
divided equally between the parties.
(b) Judgment upon the award rendered by the arbitrator(s)
may be entered in any court having jurisdiction thereof, and shall be
enforceable against the parties.
-19-
<PAGE> 20
IN WITNESS WHEREOF, the parties have duly caused this Agreement to be
executed as of the day and year set forth below.
CONNECTIVE THERAPEUTICS, INC.
By:
------------------------------------------
Thomas G. Wiggans
President and
Chief Executive Officer
SMITHKLINE BEECHAM PROPERTIES, INC.
By:
------------------------------------------
Name: Donald F. Parman
----------------------------------------
Title: Vice President
---------------------------------------
SIGNATURE PAGE TO STOCK ISSUANCE AGREEMENT
